Which drugs contain methcathinone?

Methcathinone, an amphetamine analog, typically appears as a powder or as a liquid solution mixed with water. When inhaled or ingested, it produces stimulant effects similar to those of amphetamines. Relevant research has confirmed that methcathinone lacks clinical significance, and no approved pharmaceutical product contains this substance. Specific details are as follows:

Methcathinone is classified as a novel psychoactive substance (NPS) and commonly exists as a white powder or as a liquid solution mixed with water. Upon inhalation or ingestion, it induces stimulant and hallucinogenic effects comparable to those of caffeine. This substance can cause acute health complications and lead to drug dependence; overdose may result in irreversible, permanent brain damage or even death. As a controlled psychotropic substance, methcathinone is subject to strict national regulation.

After initial use of 0.5 g of methcathinone, individuals may remain awake for up to 48 hours, accompanied by symptoms such as nausea and vomiting, while remaining in a state of persistent mental excitation. Following use, users experience intense euphoria, heightened libido, reduced appetite, diminished need for sleep, and minimal fluid intake.

Methcathinone abuse can lead to numerous adverse effects, including delusions, anxiety, tremors, insomnia, malnutrition, dehydration, excessive sweating, abdominal pain, epistaxis (nosebleeds), and generalized body aches. Intravenous administration produces effects within 1–2 minutes, whereas intranasal administration takes 5–15 minutes to take effect. Methcathinone carries a high potential for psychological dependence, though its addictive potency is somewhat lower than that of methamphetamine. Its duration of action typically lasts 4–6 hours.